Articles published by MarketBeat
Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504 ↗
September 27, 2026
Tamboran Resources Q4 Earnings Call Highlights ↗
September 27, 2026
ThredUp Posts Record Q2, Navigates More Price-Sensitive Shoppers ↗
September 27, 2026
Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials Advance ↗
September 27, 2026
PRA Group Highlights Strong NPL Supply, Cost Cuts and $150M Buyback Plan ↗
September 27, 2026
Data Centers Got the AI Hype—But Office REITs May Get the Rent Hikes ↗
September 27, 2026
2 Cybersecurity Stocks Breaking Out as AI Continues to Be a Tailwind ↗
September 27, 2026
3 More AI Infrastructure Plays Beyond the Big Names ↗
September 27, 2026
Commerzbank CEO Says UniCredit Approval Could Come by Early Next Year ↗
September 27, 2026
CAVA Stock Slips: Sector Fear or Valuation Reality? ↗
September 27, 2026
Why Equal-Weight Funds Hide A Yield Curve Catch ↗
September 27, 2026
5 Scary-Good Stocks With Strong October Catalysts and Breakout Potential ↗
September 27, 2026
BrightSpring Health Targets Growth Through Specialty Pharmacy, M&A and AI ↗
September 27, 2026
Brady Targets $14B Market After Transformative Honeywell IPS Acquisition ↗
September 27, 2026
iA Financial Sees 10%+ EPS Growth as $1.1B Capital Bolsters Wealth Push ↗
September 27, 2026
Evolution Petroleum Eyes Cash-Flow Growth With Midland Basin Royalty Deal ↗
September 27, 2026
Valmont Industries Targets $35 EPS by 2029 on Utility Infrastructure Boom ↗
September 27, 2026
Haverty Furniture Sees Design Sales Fuel Growth as Freight Costs Rise ↗
September 27, 2026
Genmab Eyes Three Pivotal Phase III Cancer Readouts in Q4 ↗
September 26, 2026
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.